person · Reporting owner
Shankman Michael Elliot
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lexaria Bioscience Corp.LEXX · Entity 7641 | Chief Financial Officer | May 15, 2025 | May 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lexaria Bioscience Corp.
Report date May 15, 2025 · Filed May 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2030-05-15 | Direct | 100,000 |
Reported balance
After 2025-05-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-15 · Grant · Acquired 50,000 · Balance 100,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.17 · Expires 2029-10-01 | Direct | 50,000 |
Reported balance
Holding disclosure · report date 2025-05-15 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance 50,000 F1: 20,000 options are exercisable as of February 28, 2025, an additional 15,000 options are exercisable on August 31, 2025 and the remaining 15,000 options are exercisable on August 31, 2026 |
Filing footnotes · ownership attribution and instrument terms
F1: 20,000 options are exercisable as of February 28, 2025, an additional 15,000 options are exercisable on August 31, 2025 and the remaining 15,000 options are exercisable on August 31, 2026
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2025 Filed May 16, 2025 16:51 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 50,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001348362-25-000007 · primary_doc.xml · derivative · entry 2 Shankman Michael Elliot · CIK 0002035175 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 50,000 shares Expires 2030-05-15 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.